Evotec SE has grown revenue 8.8% a year over three years and 12% a year over five. Revenue growth, 3-year annual rate: +8.8% (Drug Manufacturers - Specialty & Generic median +13%). Revenue growth, 5-year rate: +12%, growth has slowed since the five-year average. Years of annual history on file: 6, FY2019 to FY2024, as filed.

EVOEvotec SE

Healthcare

$1.57-61% 1Y

$1.57

$1.5352 weeks$4.15

Is it growing?

Mixed

Neither accelerating nor breaking down: nothing decisive, though operating margin narrowing (−27.6 points).

1 to watch, 1 neutral, 1 without data

Revenue trend+2% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Margin direction−27.6 points operating

Trailing-twelve-month operating margin, -17.9% now against 9.7% a year earlier.

All from SEC EDGAR, as of Dec 31, 2024.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is EVO growing?

Evotec SE has grown revenue 8.8% a year over three years and 12% a year over five.

+8.8%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · steady growth, ahead of inflation · compounded from fiscal years as filed

Revenue growth, 5-year rate: +12%
Revenue growth, 5-year rate · +8.8% over three · growth has slowed since the five-year average
Years of annual history on file: 6
Years of annual history on file · FY2019 to FY2024, as filed

Details›